Cryo-Save is listed on NYSE Euronext Amsterdam (ticker: CRYO) and is a profitable, cash generative business, which pays a dividend. Cryo-Save has a highly scalable business model with significant operational gearing.

In being the leading international family stem cell bank, Cryo-Save recognises its responsibility to proactively contribute to building knowledge and expertise in adult stem cell applications and research. Cryo-Save’s educational program aims to increase global awareness of stem cell therapy and the potential of regenerative medicine amongst healthcare professionals and local communities. This education provides the fundamentals for Cryo-Save’s sustainable growth; increasing both market size and market share in existing markets.